Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX168 in ANCA-associated vasculitis
ISRCTN19848432Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 2 trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (3 arms), sponsored by ChemoCentryx. Primary endpoint: Safety and efficacy based on Birmingham Vasculitis Activity Score at Day 169. Started Sep 2014; status: completed.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on ISRCTN19848432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19848432.